



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/649,433	08/26/2003	Jerome S. Schultz	03-016	5277

7590 08/25/2005

Parrish Law Offices  
Suite 200  
615 Washington Road  
Pittsburgh, PA 15228

EXAMINER

TSAY, MARSHA M

ART UNIT	PAPER NUMBER
----------	--------------

1653

DATE MAILED: 08/25/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.

10/649,433

Applicant(s)

SCHULTZ ET AL.

Examiner

Marsha M. Tsay

Art Unit

1653

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☐ Responsive to communication(s) filed on \_\_\_\_.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-17 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-17 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |   |  |
|---|--|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. ____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                  | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)            |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date ____ | 6) <input type="checkbox"/> Other: ____  |

### **DETAILED ACTION**

Claims 1-17 are pending and currently under examination.

Priority: The benefit date is August 26, 2002, for the purpose of prior art.

#### ***Claim Rejections - 35 USC § 112***

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 4-6, 8-13, 16-17 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 4-5, 8-9, 16-17 recite EBFP, YFP and GFP. It is acknowledged that the specification provides a definition for EBFP, YFP, and GFP; however, Applicants should provide a definition of what EBFP is in order to clarify the claim and clearly define what is being claimed.

Claim 5c recites said third moiety C is GFP. There is insufficient antecedent basis for the limitation "C" in the claim.

Claim 6 is drawn to a protein having the plasmid sequence shown in Figure 8. A sequence reference should be provided instead of a figure.

Claims 10-13 are included in this rejection because they are dependent on claim 8.

***Claim Rejections - 35 USC § 102***

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claim 1 is rejected under 35 U.S.C. 102(b) as being anticipated by Tsien et al. (US 5998204). Tsien et al. teach fluorescent protein sensors for detection of analytes. Tsien et al. teach the fluorescent indicator includes a binding protein moiety, a donor fluorescent protein moiety, and an acceptor fluorescent protein moiety (col. 1, lines 51-54). The donor and acceptor fluorescent protein moieties are bound to a binding protein moiety that changes conformation upon binding the analyte (col. 6, lines 47-50; claim 1a). This change in conformation also leads to a change in relative position and orientation of the donor and acceptor fluorescent protein moieties, thereby altering the relative amounts of fluorescence from the two fluorescent protein moieties (col. 6, lines 50-54; claim 1b). Tsien et al. teach the binding of the analyte changes the ratio of the amount of light emitted by the donor and acceptor fluorescence protein moieties wherein the ratio between the two emission wavelengths provides a measure of the concentration of the analyte in the sample (col. 6, lines 55-60; claim 1c). In figure 1, Tsien et al. describe the donor fluorescent protein moiety is covalently linked to a first region (e.g., the amino terminus) of the binding protein moiety, and the acceptor fluorescent protein moiety is covalently linked to a second region (e.g., the carboxy

Art Unit: 1653

terminus) of the binding protein moiety such that the donor and acceptor moieties move closer together upon binding the analyte (col. 6, lines 61-67; claim 1).

Claims 1-3 are rejected under 35 U.S.C. 102(b) as being anticipated by Lakowicz et al. (US 6197534). Lakowicz et al. teach biosensors for detecting analytes, such as glucose, by genetically engineering a protein for site-specific positioning of allosteric signal transducing molecules. In example 4, Lakowicz et al. teach a specific glucose sensor comprising a GGBP (glucose/galactose binding protein) fusion protein with fluorophores at both the C-terminal and N-terminal positions (col. 9, lines 44-46; claim 1, 2). Lakowicz disclose the protein is an *E.coli* glucose/galactose protein (GGBP) (col. 4, lines 21-22). In Figure 18, Lakowicz et al. teach a donor molecule Green Fluorescent Protein (GFP) is attached at the C terminal and an acceptor molecule Blue Fluorescent Protein (BFP) is attached at the N-terminal of GGBP (col. 9, lines 47-49; claim 1, 2). The donor and acceptor molecules or moieties are positioned on GGBP such that binding of glucose causes a conformational change to the GGBP (col. 9; lines 54-56; claim 1, 2). The conformational change brings the donor and acceptor fluorophores closer together so that emission from the donor fluorophore GFP is quenched by absorbance by the acceptor fluorophore BFP (col. 9, lines 55-60; claim 1-3).

### ***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

Art Unit: 1653

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-3, 5, 7, 9, 14 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lakowicz et al. (US 6197534). Lakowicz et al. teach biosensors for detecting analytes, such as glucose, by genetically engineering a protein for site-specific positioning of allosteric signal transducing molecules. Lakowicz et al. disclose Glucose/Galactose binding protein of *Escherichia coli* (GGBP) is employed as a sensing molecule and fused with fluorophore molecules bound to each side and where conformational changes of GGBP upon glucose binding can shift the positions of the fluorophores and fluorescent energy transfers between the donor and acceptor fluorophore molecules (col. 5, lines 55-66). Lakowicz et al. teach an actual working example of a GGBP (glucose/galactose binding protein) fusion protein with GFP attached at the C terminal and BFP is attached at the N-terminal (col. 9, lines 44-50). Lakowicz disclose the protein is an *E.coli* glucose/galactose protein (GGBP) (col. 4, lines 21-22). Lakowicz et al. also disclose the glucose sensors may be used to measure glucose concentrations present in extracted interstitial fluid (col. 6, lines 9-12). For a GGBP-based sensor, the motion of the two domains of the proteins is needed and should occur in polymeric supports (col. 6, lines 25-26). When labeled with suitable fluorophores, spectral changes are observed wherein glucose binding is detected by changes in emission intensity or energy transfer efficiencies. Useful spectral shifts may also be observed with fluorophore-labeled fusion proteins created from GGBP or its mutants (col. 6, lines 26-35). Lakowicz et al. disclose the spectral changes shown for

Art Unit: 1653

GGBP can be measured with low cost devices such as laser diodes, light emitting diodes, or electroluminescence light sources (col. 6, lines 36-40). The sensor may also use a variety of sensing molecules, with different fluorescent labels (col. 6, lines 44-45).

It would have been obvious to a person having ordinary skill in the art to construct a biosensing system for glucose comprising a biosensor element such as a fusion protein comprising glucose binding domain fused with fluorophores such as GFP and BFP, at the N-terminal and C-terminal ends of the protein (claim 1-3, 7a), wherein the protein is placed on a surface such as a polymeric support (claim 7a), wherein the glucose sensor is placed in interstitial fluid to measure the concentration of glucose by an electroluminescence light source device (claim 7b, 7c, 14) because Lakowicz et al. disclose a glucose sensor comprising a fusion protein of GGBP with GFP and BFP attached at the N-terminal and C-terminal ends and where the glucose sensor can be employed for monitoring of glucose concentration in interstitial fluid.

Claims 1-3, 5, 9 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lakowicz et al. (US 6197534) and further in view of Fehr et al. (2002 PNAS 99(15): 9846-9851). Lakowicz et al. teach biosensors for detecting analytes, such as glucose, by genetically engineering a protein for site-specific positioning of allosteric signal transducing molecules. Lakowicz et al. disclose Glucose/Galactose binding protein of *Escherichia coli* (GGBP) is employed as a sensing molecule and fused with fluorophore molecules bound to each side and where conformational changes of GGBP upon glucose binding can shift the positions of the fluorophores and fluorescent energy

Art Unit: 1653

transfers between the donor and acceptor fluorophore molecules (col. 5, lines 55-66).

Lakowicz et al. teach an actual working example of a GGBP (glucose/galactose binding protein) fusion protein with GFP attached at the C terminal and BFP is attached at the N-terminal (col. 9, lines 44-50). Lakowicz et al. do not teach the use of YFP (yellow fluorescent protein) in a biosensor.

Fehr et al. teach the visualization of maltose uptake by fluorescent nanosensors. Fehr et al. teach the construction of a fluorescent indicator protein wherein a truncated male PCR product encoding mature maltose-binding protein (MBP) was fused between a gene encoding an enhanced cyan fluorescent protein (ECFP) and a gene encoding an enhanced yellow fluorescent protein (EYFP) (p. 9846, experimental). Fehr et al. disclose ECFP and EYFP are green fluorescent protein (GFP) variants.

It would also have been obvious to a person having ordinary skill in the art to construct a fusion protein comprising a glucose binding domain with fluorophore molecules, such as the combination of YFP and GFP (claim 5) and utilize this sensor element in a biosensing system (claim 9) because Lakowicz et al. teach and suggest that suitable fluorophores can be used in the construction of a glucose sensor fusion protein and used in a biosensing system while Fehr et al. teach the use of YFP and CFP as fluorophore molecules in a biosensor for detecting an analogous sugar molecule.

Claim 15 is rejected under 35 U.S.C. 103(a) as being unpatentable over Tsien et al. (US 5998204) and further in view of Lakowicz et al. (US 6197534). Tsien et al. teach



Art Unit: 1653

fluorescent indicators including a binding protein moiety, a donor fluorescent protein moiety, and an acceptor fluorescent protein moiety can be produced as fusion proteins by recombinant DNA technology. Tsien et al. teach a fluorescent indicator for  $\text{Ca}^{2+}$  was produced by sandwiching CaM-M13 fusion between a blue and a green GFP mutant and cloned into pRSETB (col. 22, lines 28-31). The fluorescent indicator was efficiently expressed and folded in bacteria and increased its ratio of UV-excited 510 nm to 445 nm emissions by 70% upon binding  $\text{Ca}^{2+}$  (Fig. 3) (col. 22, lines 62-65). Tsien et al. do not teach the expression of fluorescent indicators for measuring glucose.

Lakowicz et al. teach a glucose sensor comprising a GGBP (glucose/galactose binding protein) fusion protein with fluorophores at both the C-terminal and N-terminal positions (col. 9, lines 44-46). In Figure 18, Lakowicz et al. teach a donor molecule Green Fluorescent Protein (GFP) is attached at the C terminal and an acceptor molecule Blue Fluorescent Protein (BFP) is attached at the N-terminal of GGBP (col. 9, lines 47-49). Lakowicz et al. disclose the spectral changes shown for GGBP can be measured with low cost devices such as laser diodes, light emitting diodes, or electroluminescence light sources (col. 6, lines 36-40). The sensor may also use a variety of sensing molecules, with different fluorescent labels (col. 6, lines 44-45). Lakowicz et al. do not teach an expression vector coding for the glucose sensor protein and wherein the method of measuring glucose is measured within cells.

It would have been obvious to a person having ordinary skill in the art to non-invasively measure glucose concentration within a cell by introducing a plasmid/expression vector encoding a glucose binding domain fused with fluorophore

Art Unit: 1653


molecules at the N-terminal and C-terminal ends into a cell, expressing the fluorescent indicator protein, and measuring the spectral changes upon the binding of an analyte, in this instance a glucose molecule (claim 15), because Lakowicz et al. teach the detection of glucose through a fluorescence indicator protein and Tsien et al. use the same technology and teach the successful expression of a fluorescent indicator protein that measures an analyte within cells.

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Marsha M. Tsay whose telephone number is 571-272-2938. The examiner can normally be reached on M-F, 9:00am-5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Jon Weber can be reached on 571-272-0925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

  
**KAREN COCHRANE CARLSON, PH.D**  
**PRIMARY EXAMINER**

Application/Control Number: 10/649,433  
Art Unit: 1653

Page 10

August 15, 2005